26,265 Shares in Myriad Genetics, Inc. $MYGN Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 26,265 shares of the company’s stock, valued at approximately $147,000.

A number of other hedge funds also recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in shares of Myriad Genetics by 520.8% during the 1st quarter. GAMMA Investing LLC now owns 4,470 shares of the company’s stock worth $40,000 after acquiring an additional 3,750 shares in the last quarter. M.E. Allison & CO. Inc. purchased a new position in shares of Myriad Genetics in the 1st quarter valued at approximately $93,000. Blue Trust Inc. grew its stake in shares of Myriad Genetics by 57.0% in the 1st quarter. Blue Trust Inc. now owns 14,367 shares of the company’s stock valued at $127,000 after purchasing an additional 5,214 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Myriad Genetics by 2.7% in the 1st quarter. Principal Financial Group Inc. now owns 453,251 shares of the company’s stock valued at $4,020,000 after purchasing an additional 11,864 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Myriad Genetics by 600.2% in the first quarter. CWM LLC now owns 9,796 shares of the company’s stock valued at $87,000 after buying an additional 8,397 shares in the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a report on Saturday, September 27th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.45.

Myriad Genetics Stock Down 3.1%

Shares of NASDAQ MYGN opened at $7.50 on Friday. The stock’s 50 day moving average price is $6.72 and its two-hundred day moving average price is $6.11. Myriad Genetics, Inc. has a 52-week low of $3.76 and a 52-week high of $25.25. The stock has a market capitalization of $697.84 million, a P/E ratio of -1.75 and a beta of 1.97.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, January 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $156.40 million for the quarter. Myriad Genetics had a negative net margin of 47.45% and a negative return on equity of 5.17%. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. On average, analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.